,ug* kg.* min-1), and five received placebo. Complete inhibition of ex vivo platelet aggregation was seen at 0. 15 latelets play an important role in the initiation of occlusion or reocclusion of arteries at the site of high-grade stenosis or ruptured atheromatous plaques, thereby contributing significantly to cerebrovascular, cardiovascular, and peripheral vascular diseases. Platelets are also important in acute restenosis after coronary angioplasty, thrombolysis, and carotid endarterectomy and to the formation of stenoses at anastomotic sites of vascular grafts and thrombus formation at sites of indwelling catheters. [1] [2] [3] The final common mechanism in the formation of a platelet aggregate is the cross-linking of adjacent activated
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We report on the effects in man of one such nonpeptide tyrosine derivative GPIIb/IIIa antagonist, MK-383,21 testing the hypothesis that one or more dose levels of the drug would be well tolerated and would produce targeted levels of inhibition of platelet function as measured in vivo by bleeding time prolongation and ex vivo by inhibition of ADP-and collagen-induced platelet aggregation.
Methods

In Vitro Studies
In vitro studies were carried out to characterize the pharmacologic profile of MK-383 with respect to inhibition of agonist-induced aggregation and fibrinogen binding.
Platelet (3.4 1Lmol/L) and collagen (2 ,ug/mL).
These concentrations were determined as the minimal concentrations of these agonists that give full response in more than 90% of normal subjects. Aggregation was followed for 4 minutes after addition of agonist, and the maximum percent increase of light transmission obtained during this period (maximal amplitude) was calculated. Results were expressed as percent inhibition from baseline. Plasma levels of MK-383 were determined in lithium heparin anticoagulated plasma, using radioimmunoassay methodology.
For clinical safety assessment, the following parameters were studied: ECG, vital signs (blood pressure, heart rate, temperature, respirations), hematology (hemoglobin, hematocrit, red blood cell count, total and differential white blood cell count, platelet count, prothrombin time, partial thromboplastin time), blood chemistry (SGOT, SGPT, serum alkaline phosphatase, serum total bilirubin, serum creatinine, urea (Table) . This extension was statistically significant at the 0.10 pug kg-l min`infusion rate (P<.01). A mean 4.6-fold (5.0±1.3 to 22.7±6 minutes, n=3) prolongation was obtained with 0.40 ,jg * kg-min`. Bleeding times had returned to normal 3 hours after the end of the 1-hour infusion (Fig 2) .
Ex vivo platelet aggregation induced by either collagen or ADP was significantly inhibited (P<.01) 30 minutes following the start of the infusion of 0.10 jig * kg`* min1 MK-383 (Fig 2) . Complete inhibition of both collagen-and ADP-induced platelet aggregation was seen after 30 and 60 minutes at the infusion rate of 0.40 jig. kg`* min'1 with recovery to 89±4% and 55+± 12% of predose response at 4 hours after the start of infusion. No adverse effects were seen with any of the safety parameters; no changes in platelet counts were found during or after the infusion.
Based on the results of the 1-hour study, a 4-hour infusion study was completed in which 5 subjects received placebo and 15 subjects were treated with MK- (Table) and remained slightly prolonged 3 hours after infusion (7.2+1.8 minutes) (Fig 3) . The plasma half-life of MK-383 was approximately 90 minutes; pharmacokinetics of the compound will be addressed in detail elsewhere. Dose-dependent rapidonset inhibition of both collagen-and ADP-induced aggregation was seen with a near-complete inhibition of aggregation during the infusion of 0. 15 ,g kg`. min-1. Again, no changes in the safety parameters were recorded. When bleeding time extension and inhibition of ADP-induced ex vivo platelet aggregation at all doses and time points are plotted against plasma levels of the drug (Fig 4) , it is clear that inhibition of ADP-induced aggregation occurred over a very narrow concentration range, between 10 and 50 ng/mL, or 20 to 100 nmol/L, which corresponds well to the mean in vitro IC50 of 66 nmol/L for ADP-induced aggregation. On the other hand, only a modest prolongation of the bleeding time occurred over concentrations of 10 to 45 ng/mL, with a step-up in prolongation between 45 and 50 ng/mL.
Discussion
We report on the first administration to man of a nonpeptide GPIIb/IIIa-blocking agent. In preliminary in vitro studies, it was shown that MK-383 selectively inhibits GPIIb/IIIa by the finding that fibrinogen-dependent platelet aggregation induced by a variety of agonists was inhibited. However, ristocetin-induced agglutination, which proceeds through binding of von Willebrand factor to GPIb, was unaffected. Furthermore, the compound dose-dependently inhibited fibrinogen binding to activated platelets in a competitive manner.
Administration of MK-383 to human volunteers during either a 1-hour (maximum dose, 0.40 ,g* kg1 min-1) or a 4-hour (maximum dose, 0.20 ,ug kg-' min-1) intravenous infusion resulted in marked effects on ex vivo platelet aggregation. At these doses, plasma drug concentrations of MK-383 were comparable to those needed for in vitro activity. As a presumed consequence of the inhibition of platelet function, the bleeding times were prolonged. However, the concentration-effect relationship for extension of bleeding time was to the right of the relationship for inhibition of ADP aggregation. This different sensitivity has been observed with a variety of GPIIb/IIIa inhibitors in both animal models and man,25 which indicates that inhibition of platelet aggregation can occur without major effects on bleeding time. Coller et aP25 have shown a correlation between the number of GPIIb/IIIa receptors blocked by the monoclonal antibody 7E3 and the bleeding time: when 8000 to 15 000 residual receptors were available, platelet aggregation was markedly decreased, whereas the bleeding time was only mildly affected. The bleeding time, however, rapidly prolonged when the number of residual GPIIb/IIIa receptors decreased below 10 000. The same mechanism may explain the rather large differences in bleeding times that were seen with small differences in plasma levels of MK-383 around 45 ng/mL. In this respect, it is noteworthy that in some thrombosis models, GPIIb/IIIa antibodies proved to be effective at levels that only mildly affected bleeding times.26 ' their use to acute thrombotic situations such as reocclusion following thrombolysis. To be useful for preventive therapy, an orally active compound is needed. The development of this still orally inactive but well tolerated and effective nonpeptide inhibitor, MK-383, is one step closer toward this goal.
